Tanvex BioPharma, Inc. (TPE:6541)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
56.70
+2.80 (5.19%)
Jul 10, 2025, 1:30 PM CST
-16.62%
Market Cap 13.52B
Revenue (ttm) 81.18M
Net Income (ttm) -1.43B
Shares Out 238.49M
EPS (ttm) -8.06
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,888,835
Average Volume 523,498
Open 54.00
Previous Close 53.90
Day's Range 53.50 - 58.60
52-Week Range 43.95 - 82.00
Beta -0.04
RSI 59.83
Earnings Date Aug 8, 2025

About Tanvex BioPharma

Tanvex BioPharma, Inc., a biopharmaceutical company, researches, develops, manufactures, and sells biosimilar products in Taiwan and the United States. It focuses on delivering biosimilars which target neutropenia, breast cancer, metastatic colorectal cancer, and psoriasis. The company’s products pipeline includes TX01 and TX-05 which have completed Phase III clinical trials; TX-04 and TX-16 that are in Phase I clinical trial; and TX-52 and other products which are in pre-clinical trial. The company was formerly known as Ruenvex Biotech, Inc. T... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2013
Employees 198
Stock Exchange Taiwan Stock Exchange
Ticker Symbol 6541
Full Company Profile

Financial Performance

In 2024, Tanvex BioPharma's revenue was 34.68 million, a decrease of -43.53% compared to the previous year's 61.41 million. Losses were -1.38 billion, -35.35% less than in 2023.

Financial Statements

News

There is no news available yet.